Search Results

Displaying Results 1-1 of 1 "'CLDT'"
Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.

Mar 31, 2026, 08:13 ET 3SBio Announces 2025 Annual Results: Dual Engines of Innovative R&D and Global Collaboration Propel Revenue Past RMB 10 Billion Milestone

thrombopoietin product, obtained approval for a new indication in December 2025—for the treatment of chronic liver disease-related thrombocytopenia (CLDT) in patients scheduled to undergo surgery (including diagnostic procedures). This approval provides a rapid-acting, stable and safe platelet-boosting

More news about: 3SBio Inc.

Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.